A phase I/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancer

Yu, WJ; Ye, F; Yuan, X; Ma, YL; Mao, CM; Li, XQ; Li, J; Dai, CH; Qian, FH; Li, JR; Fan, XJ; Zhou, YP; Wang, DQ; Guo, ZH; An, HZ; Zhang, MH; Chen, DY; Xia, S

Xia, S (corresponding author), Jiangsu Univ, Sch Med, Dept Immunol, Zhenjiang, Jiangsu, Peoples R China.; Chen, DY (corresponding author), Jiangsu Univ, Dept Oncol, Affiliated Hosp, Zhenjiang, Jiangsu, Peoples R China.; Zhang, MH (corresponding author), Tsinghua Univ, Sch Med, Beijing, Peoples R China.

BMC CANCER, 2021; 21 (1):

Abstract

Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, have achieved good efficacy in EGFR mutation-p......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索